Tisopurine

Summary

Tisopurine (CHEMBL119423) is an approved small molecule (ATC M04AA02); indicated across 1 condition including gout.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M04AA02
• Indications: 1 condition
• Chemistry: 152.18 Da · C5H4N4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL119423
Name	Tisopurine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	135445058
ATC	M04AA02
Molecular formula	C5H4N4S
Molecular weight	152.18
InChIKey	PYAOPMWCFSVFOT-UHFFFAOYSA-N

SMILES: C1=NNC2=C1C(=S)N=CN2

IUPAC name: 1,7-dihydropyrazolo[5,4-d]pyrimidine-4-thione

Also known as: Exuracid, NSC-1392, Tisopurina, Tisopurine, TISOPURINE

Patent coverage: 180 distinct patent families (545 SureChEMBL compound mentions), from 7 matched compound structure(s). One matched structure accounts for 366 (67%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
gout	4	MONDO:0005393	EFO:0004274

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).